STERIS plc (STE) Risk Factors

Recent key developments

Concrete developments — dated events, named agreements and instruments, legal proceedings — that STERIS plc surfaced in its latest filing.

• The United States-Mexico-Canada Agreement requires a formal six-year joint evaluation, with the first review expected to commence on July 1, 2026.2026-07-01
• The One Big Beautiful Bill Act (OBBBA) was signed on July 4, 2025, which may reduce Medicaid funding and negatively impact customers.2025-07-04
• The Inflation Reduction Act added a corporate alternative minimum tax (CAMT) beginning fiscal 2023.2023
• The OECD's Multilateral Instrument (MLI) came into effect on July 1, 2018, and may modify tax treaties to prevent treaty abuse.2018-07-01
• European Union adopted the CSRD in 2023, with proposed amendments in 2025 entering into force in March 2026, and transposition required in 2027.2026-03
• In 2016, the EPA changed the cancer risk basis for EO and determined that EO is carcinogenic to humans.2016
• We entered into binding confidential settlement agreements in March and October 2025 to pay up to approximately $48.2 million to resolve substantially all personal injury claims related to EO exposure pending in the Circuit Court of Cook County, Illinois.2025-03
• As of March 31, 2026, STERIS had approximately $1,931.7 million of indebtedness outstanding, consisting of $1,350.0 million of Senior Public Notes issued April 1, 2021, $557.8 million of Private Placement Senior Notes, and $37.8 million of borrowings under its Revolving Credit Facility.2026-03-31
• Acquisition of Cantel Medical completed in June 2021.2021-06
• As of March 31, 2026, we had recorded goodwill of $4 billion and other intangible assets, net, of $2 billion.2026-03-31